Company: VERA
Filing Date: 2025-04-03
Form Type: DEF 14A
Source: 0001140361-25-012034
Chunk: 65

Company: Vera Therapeutics, Inc.
Filing Date: 2025-04-03
Form: DEF 14A
Chunk 65
---
      Common Stock 
         Purchased |     | Aggregate Cash 
 Purchase Price |
| Fidelity Management & Research Company LLC(1) |     |           800,000 |     |    $24,800,000 |
| Commodore Capital LP(2)                       |     |           450,000 |     |    $13,950,000 |
| Kynam Capital Management, LP(3)               |     |           300,000 |     |     $9,300,000 |
| Sofinnova Venture Partners X, L.P.(4)         |     |           161,290 |     |     $4,999,990 |

| (1) | Entities affiliated with Fidelity Management & Research Company LLC collectively beneficially owned more than 5% of our outstanding capital stock. |

| (2) | Commodore Capital LP owned more than 5% of our outstanding capital stock. |

| (3) | Kynam Capital Management, LP owned more than 5% of our outstanding capital stock. |

| (4) | Maha Katabi, Ph.D., is a general partner at Sofinnova Venture Partners X, L.P. and a member of our Board. Sofinnova Venture Partners X, L.P. owned more than 5% of our outstanding capital stock. |

Participation in October 2024 Follow-on Public Offering In October 2024, we entered into an underwriting agreement (“October 2024 Underwriting Agreement”) with J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Cantor Fitzgerald & Co. ., as representatives of the several underwriters, relating to a follow-on underwritten public offering of shares of our Class A common stock (“October 2024 Follow-on Offering”). Pursuant to the October 2024 Underwriting Agreement, we issued and sold an aggregate of 8,214,286 shares of our Class A common stock to the underwriters, including 1,071,428 shares of Class A common stock that we issued and sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares in connection with the October 2024 Follow-on Offering, at a price to the public of $42.00 per share. Our October 2024 Follow-on Offering closed on October 31, 2024. Certain holders of more than 5% of our capital stock (including shares of Class A common stock acquired in the offering)